Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.

Three Motley Fool contributors think they've identified a handful of healthcare stocks that are underdogs. Here's why they view Bristol Myers Squibb(NYSE: BMY), Moderna(NASDAQ: MRNA), and Pfizer(NYSE: ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

T Helper 17 (T H 17) cells may be a potential biomarker to predict the risk of immune-related adverse events (irAEs) in ...

Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th anniversary this month since its release by Ono Pharmaceutical Co under the brand ...

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.